Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- IPN.PA
- Price
- 100.90
- Stock movement down
- -0.30 (-0.30%)
- Company name
- Ipsen SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Markedsværdi
- 8.35B
- Ent værdi
- 10.36B
- Pris/omsætning
- 1.68
- Pris/bog
- 2.06
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- 19.21%
- Efterfølgende P/E
- 9.52
- Fremtidig P/E
- 9.83
- PEG
- -
- EPS-vekst
- 10.56%
- 1 års afkast
- -12.94%
- 3 års afkast
- 3.37%
- 5 års afkast
- 4.27%
- 10 års afkast
- 5.42%
Senest opdateret: 2025-06-22
UDBYTTE
IPN.PA betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | 9.52 |
| Pris til OCF | 6.27 |
| Pris til FCF | 7.49 |
| Pris til EBITDA | 5.16 |
| EV i forhold til EBITDA | 6.40 |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 1.68 |
| Pris til egenkapital | 2.06 |
| EV i forhold til salg | 2.09 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 82.71M |
| EPS (TTM) | 10.50 |
| FCF pr. aktie (TTM) | 13.35 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 4.97B |
| Bruttofortjeneste (TTM) | 4.08B |
| Driftsindkomst (TTM) | 1.11B |
| Nettoindkomst (TTM) | 876.30M |
| EPS (TTM) | 10.50 |
| EPS (1 år frem) | 10.27 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 82.12% |
| Driftsmargin (TTM) | 22.42% |
| Fortjenstmargin (TTM) | 17.65% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 485.40M |
| Nettotilgodehavender | 719.20M |
| Omsætningsaktiver i alt | 1.90B |
| Goodwill | 685.30M |
| Immaterielle aktiver | 2.88B |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 6.55B |
| Kreditor | 857.60M |
| Kortfristet/nuværende langsigtet gæld | 490.20M |
| Summen af kortfristede forpligtelser | 1.67B |
| Sum gæld | 2.50B |
| Aktionærernes egenkapital | 4.05B |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | 1.33B |
| Investeringsudgifter (TTM) | 175.50M |
| Fri pengestrøm (TTM) | 1.11B |
| Udbetalt udbytte (TTM) | 214.00M |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | 21.66% |
| Afkast af aktiver | 13.38% |
| Afkast af investeret kapital | 20.96% |
| Kontant afkast af investeret kapital | 26.65% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 101.60 |
| Daglig høj | 102.40 |
| Daglig lav | 100.20 |
| Daglig volumen | 132K |
| Højeste gennem alle tider | 153.15 |
| 1 års analytiker estimat | 129.50 |
| Beta | 0.57 |
| EPS (TTM) | 10.50 |
| Udbytte pr. aktie | - |
| Ex-div dato | 4 Jun 2025 |
| Næste dato for resultatpræsentation | 31 Jul 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| IPN.PA | S&P500 | |
| Nuværende prisfald fra top notering | -34.12% | -3.04% |
| Højeste prisfald | -75.87% | -56.47% |
| Højeste efterår dato | 18 Mar 2020 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -25.69% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 31 days | 12 days |
| Maks. tid til nyt højdepunkt | 1742 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
8.35B
Markedsværdi kategori
Mid-cap
Beskrivelse
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Personale
5325
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
France
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Aggregated presentation by day and by market Statement of transactions in own shares from June 30th to July 4th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of the...
8. juli 2025
IRIC and IRICoR today announced the start of a Phase 1 clinical trial of its small molecule therapy for solid tumors licensed to Ipsen. This marks a major milestone in the strategic collaboration betw...
8. juli 2025
Aggregated presentation by day and by market Statement of transactions in own shares from June 23rd to June 27th 2025 Name of the issuer Identity code of the issuer (Legal Entity Identifier) Day of th...
1. juli 2025
Aggregated presentation by day and by market Statement of transactions in own shares from June 16th to June 20th 2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the...
24. juni 2025
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somato...
20. juni 2025
Aggregated presentation by day and by market Statement of transactions in own shares from June 09th to June 13th 2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the...
17. juni 2025
Aggregated presentation by day and by market Statement of transactions in own shares from June 2nd to June 6th 2025 Name of the issuerIdentity code of the issuer (Legal Entity Identifier) Day of the t...
13. juni 2025
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the ...
12. juni 2025
PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has a...
2. juni 2025
Regulated information Ipsen initiates a share buy-back program to cover its free employee share-allocation plan PARIS, FRANCE, 2 June 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it h...
2. juni 2025
Næste side